Item 1. Security and Issuer
The information set forth in response to each separate Item below shall be deemed to be a response to all Items where such information is relevant.
This Amendment No. 1 (“Amendment No. 1”) is being filed by the undersigned to amend the Schedule 13D filed with the SEC on June 1, 2021, (the “Original 13D” and, as amended by Amendment No. 1, the “Schedule 13D”) relating to shares of common stock (the “Common Stock”), of GoodRx Holdings, Inc., a Delaware corporation (the “Issuer”), whose principal executive office is located at 2701 Olympic Boulevard, Santa Monica, California 90404. Except as set forth herein, the Original 13D is unmodified and remains in full force and effect. Capitalized terms used herein and not otherwise defined in this Amendment No. 1 have the meanings set forth in the Original 13D.
Item 2. Identity and Background
The Schedule 13D is being filed by the following entities (each a “Reporting Person” and collectively, the “Reporting Persons”):
| 1. | Spectrum Equity VII, L.P. (“SE VII”) |
| 2. | Spectrum Equity Associates VII, L.P. (“Spectrum Equity Associates”) |
| 3. | Spectrum VII Investment Managers’ Fund, L.P. (“Spectrum VII Investment Managers’ Fund”) |
| 4. | Spectrum VII Co-Investment Fund, L.P. (“Spectrum VII Co-Investment Fund”) |
| 5. | SEA VII Management, LLC (“Management LLC”) |
Information with respect to the members and executive officers of Management LLC (collectively, the “Related Persons”), including the name, business address, present principal occupation or employment and citizenship of each of the Related Persons is listed on the attached Schedule A, which is incorporated herein by reference.
During the last five years, neither the Reporting Persons nor any Related Persons (i) has been convicted in any criminal proceeding (excluding traffic violations or similar misdemeanors) or (ii) was a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.
Item 4. Purpose of Transaction.
Item 4 of the Schedule 13D is hereby amended to include the following at the end thereof:
On November 21, 2023, the Selling Stockholders agreed to sell an aggregate 12,000,000 Class A Shares to the Issuer for net proceeds of $65,640,000 (the “Repurchase”).
Item 5. Interest in the Securities of the Issuer
Items 5(a), (b) and (c) of the Schedule 13D is hereby amended and restated as follows:
(a) and (b)
The information contained on the cover pages of this Schedule 13D, which is incorporated herein by reference, gives effect to the closing of the Stock Purchase Agreement transaction, which is expected to occur on November 27, 2023. All such ownership percentages of the securities reported in this Schedule 13D were calculated assuming 116,545,403 shares outstanding based upon 92,400,328 Class A Shares of the Issuer issued and outstanding as of September 30, 2023 as reported on the 10-Q, as (i) increased by 36,145,075 Class B Shares held by the Reporting Persons and (ii) decreased by the 12,000,000 Class A Shares purchased by the Issuer from Spectrum Equity VII, L.P , Spectrum VII Investment Managers’ Fund, L.P. and Spectrum VII Co-Investment Fund, L.P (together, the “Selling Stockholders”).